{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.173","value":"1.12"},{"groupId":"OG001","spread":"0.264","value":"1.37"},{"groupId":"OG002","spread":"0.467","value":"1.70"},{"groupId":"OG003","spread":"0.399","value":"1.42"},{"groupId":"OG004","spread":"0.369","value":"1.47"},{"groupId":"OG005","spread":"0.368","value":"1.46"},{"groupId":"OG006","spread":"0.385","value":"1.76"},{"groupId":"OG007","spread":"0.160","value":"1.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.229","value":"1.15"},{"groupId":"OG001","spread":"0.252","value":"1.35"},{"groupId":"OG002","spread":"0.325","value":"1.71"},{"groupId":"OG003","spread":"0.962","value":"1.80"},{"groupId":"OG004","spread":"0.492","value":"1.62"},{"groupId":"OG005","spread":"0.486","value":"1.63"},{"groupId":"OG006","spread":"0.418","value":"1.78"},{"groupId":"OG007","spread":"0.314","value":"1.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"66"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"SG3199: Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"description":"AI for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199). AI is the ratio of area under the serum concentration-time curve (AUC) from 0 to 21 days for Cycle 2 divided by AUC from 0 to 21 days for Cycle 1 (Q3W schedule: 3 week cycle length; Q6W schedule: 6 week cycle length). It is the increase in drug plasma concentration after multiple dosing until a steady state is reached.\n\nResults for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Part 1: 15 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG001","title":"Part 1: 30 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG002","title":"Part 1: 60 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG003","title":"Part 1: 90 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG004","title":"Parts 1 and 2: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG005","title":"Parts 1 and 2: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG006","title":"Part 1: 200 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG007","title":"Part 1: 200 μg/kg Q6W"}],"paramType":"MEAN","populationDescription":"Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)","title":"Accumulation Index (AI) for ADCT-402","type":"SECONDARY","unitOfMeasure":"ratio"}